"Tacrolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
| Descriptor ID |
D016559
|
| MeSH Number(s) |
D02.540.505.810
|
| Concept/Terms |
Anhydrous Tacrolimus- Anhydrous Tacrolimus
- Tacrolimus, Anhydrous
- Tacrolimus Anhydrous
- Anhydrous, Tacrolimus
|
Below are MeSH descriptors whose meaning is more general than "Tacrolimus".
Below are MeSH descriptors whose meaning is more specific than "Tacrolimus".
This graph shows the total number of publications written about "Tacrolimus" by people in this website by year, and whether "Tacrolimus" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 14 | 3 | 17 |
| 1996 | 10 | 4 | 14 |
| 1997 | 7 | 5 | 12 |
| 1998 | 9 | 5 | 14 |
| 1999 | 2 | 3 | 5 |
| 2000 | 3 | 2 | 5 |
| 2001 | 9 | 7 | 16 |
| 2002 | 12 | 1 | 13 |
| 2003 | 15 | 8 | 23 |
| 2004 | 9 | 7 | 16 |
| 2005 | 15 | 5 | 20 |
| 2006 | 10 | 6 | 16 |
| 2007 | 17 | 7 | 24 |
| 2008 | 13 | 9 | 22 |
| 2009 | 10 | 7 | 17 |
| 2010 | 11 | 9 | 20 |
| 2011 | 7 | 16 | 23 |
| 2012 | 12 | 8 | 20 |
| 2013 | 10 | 5 | 15 |
| 2014 | 8 | 5 | 13 |
| 2015 | 11 | 9 | 20 |
| 2016 | 12 | 10 | 22 |
| 2017 | 11 | 6 | 17 |
| 2018 | 4 | 6 | 10 |
| 2019 | 3 | 5 | 8 |
| 2020 | 10 | 6 | 16 |
| 2021 | 7 | 5 | 12 |
| 2022 | 3 | 5 | 8 |
| 2023 | 3 | 9 | 12 |
| 2024 | 5 | 2 | 7 |
Below are the most recent publications written about "Tacrolimus" by people in Profiles.
-
Calcineurin/NFAT inhibitors maintain cognition in a preclinical prevention study in an aging canine model of Alzheimer disease. Neurobiol Aging. 2025 02; 146:1-14.
-
Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients. Ther Drug Monit. 2025 Feb 01; 47(1):169-173.
-
A Review of the Vitiligo Literature to Standardize Expression of Disease Severity. J Drugs Dermatol. 2024 Oct 01; 23(10):842-846.
-
CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis. Transplant Cell Ther. 2024 Nov; 30(11):1092-1098.
-
Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus. Transplant Proc. 2024 Sep; 56(7):1671-1677.
-
Age-Related Brain Atrophy and the Positive Effects of Behavioral Enrichment in Middle-Aged Beagles. J Neurosci. 2024 May 15; 44(20).
-
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians. Ann Transplant. 2024 Mar 12; 29:e943498.
-
Conservative Management of Penile and Urethral Lichen Sclerosus: A Systematic Review. J Urol. 2024 Mar; 211(3):354-363.
-
Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients. Transpl Infect Dis. 2024 Feb; 26(1):e14209.
-
Subtle Changes in Tacrolimus Levels Have an Impact on Early Donor-Specific Antibodies in Kidney Transplantation. Prog Transplant. 2023 Dec; 33(4):335-340.